casinoplayingcards| Lepu Bio-B: Three clinical research results will be announced at the 2024 ASCO Annual Meeting

Lepu Bio-B (02157) announced that the company is innovative drug candidates and combination therapies (including antibody drug conjugates ('ADC ') MRG004A, MRG003 and HX008casinoplayingcardsThe results of three clinical studies of the combination therapy of HX008 and nirapali) were announced at the 2024 American Society of Clinical Oncology ('ASCO ') Annual Meeting.